PTC Therapeutics(US:PTCT)2026-02-19 22:32Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide as of December 31, 2025 [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [8][15] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential multi-billion dollar global revenue opportunity for Sephience, citing its differentiated profile and broad uptake [8][12] - The company anticipates reaching cash flow break-even in 2026, a significant milestone [7][20] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [19] - The FDA has requested an additional study for Vatiquinone, which the company plans to pursue [39] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and contributions from mature products [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Many adults previously lost to follow-up are now seeking therapy due to social media awareness and positive patient experiences shared online [30][31] Question: What are the dynamics for Vatiquinone's additional study? - The FDA suggested an open-label or single-arm study with a natural history comparator group, which the company plans to discuss further [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, indicating strong early adoption [46][47] Question: How will Sephience's growth in Europe be affected after the free pricing period? - The company anticipates maintaining a strong price based on the clinical data package and ongoing negotiations [51][53]